Biotech company Viking Therapeutics is making waves in the weight loss drug market, positioning itself as a strong contender or potential acquisition target. With the industry projected to reach a value of $100 billion by the end of the decade, Viking is among several companies vying for a piece of the pie.
Competing with established players like Eli Lilly and Novo Nordisk, Viking’s experimental obesity treatment has shown promising results, with some analysts touting it as “best-in-class.” In fact, in a midstage trial, Viking’s injectable drug demonstrated even greater weight loss potential than Eli Lilly’s Zepbound, leading to a 120% surge in Viking’s shares.
These developments position Viking as a formidable player in a market that is ripe for further growth and innovation.
2024-03-03 09:04:46
Original from www.cnbc.com
